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Abstract
Folate has received international attention regarding its role in the risk-reduction of birth defects, specifically neural tube defects (NTDs). In 1998,
health officials in Canada, like the United States, mandated the addition of folic acid to white flour and select grain products to increase the folate
intake of reproductive-aged women. Subsequent to this initiative there has been an increase in blood folate concentrations in Canada and a 50
% reduction in NTDs. Many countries, including Korea, have not mandated folic acid fortification of their food supply. Reasons vary but often
include concern over the masking of vitamin B12 deficiency, a belief that folate intakes among womenare adequate, low priority relative to other
domestic issues, and the philosophy that individuals have the right not to consume supplemental folic acid if they so choose. Prior to folic acid
fortification of the food supply in Canada, the folate intakes of women were low, and their blood folate concentrations while not sufficiently low 
to produce overt signs of folate deficiency (eg. anemia) were inconsistent with a level known to reduce the risk of an NTD-affected  pregnancy. 
The purpose of this article is to describe the role of folate during the periconceptional period, pregnancy, and during lactation. The rationale for,
and history of recommending folic acid-containing supplements during the periconceptional period and pregnancy is described as is folic acid fortification
of the food supply. The impact of folic acid fortification in Canada is discussed, and unresolved issues associated with this policy described. While
the incidence of NTDs in Canada pre-folic acid fortification were seemingly higherthan that of Korea today, blood folate levels of Korean women
are strikingly similar. We will briefly explore these parallels in an attempt to understand whether folic acid fortification of the food supply in Korea
might be worth consideration
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Introduction1)
Folate, a water-soluble B vitamin, is a generic descriptor for 
a host of structurally similar compounds that contain a pteroy-
lmonoglutamic acid or a folic acid core (Fig. 1). This consists 
of a p-aminobenzoic acid molecule linked to a pteridine ring 
at one end and glutamic acid at the other. Pteroylmonoglutamic 
acid or folic acid, is seldom found in nature, but because of 
its stability and low cost, is synthesized and used in vitamin 
supplements and as a fortificant in food. By convention, the term 
folic acid is typically reserved to describe the synthetic form 
of the vitamin. Folates function in many coenzyme forms in 
acceptance, redox processing and transfer of one-carbon units. 
They are best known for their key role in the synthesis and repair 
of DNA, and methylation of homocysteine to regenerate 
methionine (Fig. 2).
Inadequate folate intakes have been associated in the literature 
with a number of negative health outcomes in humans including 
neural tube defects (NTDs), cleft lip and/or palate, low infant 
birth weight, abruptio placenta, preeclampsia, spontaneous abor-
tion, stillbirth, macrocytic anemia, cardiovascular disease and 
neuropsychiatric disorders (Lucock, 2000; Picciano et al., 1994; 
Ray, 1998; Seshadri et al., 2002; Tamura & Picciano, 2006). 
Suboptimal intakes have also been shown in some studies to play 
a role in the development of several malignancies including 
cancer of the colorectum, breast, cervix, lung, pancreas, eso-
phagus, and stomach as well as neuroblastoma and leukemia 
(French  et al., 2003; Kim, 1999; Kim, 2003; Kim, 2004b) 
Canadian Health authorities concluded that the evidence in 
support of NTD prevention was sufficiently robust that it 
mandated folic acid fortification of white flour and select grain 
products as of November 1998. Many countries globally, 
however, have not adopted a folic acid fortification policy. Many 
have not done so because of concern over the potential adverse 
effects of folic acid, in particular the concern that high intakes 
of folic acid may delay the diagnosis of B12 deficiency by 
correcting the characteristic megaloblastic anemia. 
The purpose of this article is to describe the role of folate 
during female reproduction and specifically the periconceptional 
period, pregnancy (post-closure of the neural tube), and during 
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Fig. 1. The chemical structure of folic acid or pterolylmonoglutamic acid. Other 
f o l a t e  f o r m s  a r e  d e n o t e d  b y  t h e  “R”-substitutions  found  in  the  box. Fig. 2. Simplified diagram of intracellular folate metabolism involving DNA 
biosynthesis and methylation. THF,  tetrahydrofolate;  MTHFR,  methylenetetra-
hydrofolate;  SAM,  S-adenosylmethionine;  SAH,  S-adenosylhomocysteine;  CpG, 
Cytosine-guanine  dinucleotide  sequence;  CH3  ,  methyl  group;  DNMT ( 1 ,  3 a ,  3 b ) , 
DNA methyltransferases; MTR,  methionine  synthase; MTRR,  methionine  synthase 
reductase;  TS,  Thymidylate  synthase;  DHFR,  dihydrofolate  reductase;  dUMP, 
deoxyuridine  monophosphate;  dTMP,  deoxythymidine  monophosphate; S H M T ,  
serine hydroxymethyltransferase; CBS, cystathionine β-synthase [diagram modified 
with  permission  (Kim,  2004a;  Sohn  et  al.,  2004)]
lactation. The rationale for and history of recommending folic 
acid-containing supplements during the periconceptional period 
and pregnancy in Canada is described as is the folic acid 
fortification policy. The impact of folic acid fortification is 
discussed and unresolved and immerging issues associated with 
this policy are described. While the incidence of NTDs pre-folic 
acid fortification of the food supply in Canada were higher than 
that of South Korea today, blood folate levels of Korean women 
are strikingly similar. We will briefly explore these parallels in 
an attempt to understand whether folic acid fortification of the 
food supply in South Korea might be worth consideration.
Function 
As described above, folates function in many coenzyme forms 
in acceptance, redox processing and transfer of one-carbon units. 
In order to carry out these functions, folates in nature are typically 
reduced to either di-hydro or tetrahydrofolate forms with 
hydrogens at the 5, 6, 7 and 8 positions (Fig. 1). Further, various 
one-carbon units can be carried at the N5 and N10 positions 
or bridging the same. Finally, in nature, a significant proportion 
of folates are polyglutamylated, meaning they have several 
glutamates linked together to create what is commonly referred 
to as a polyglutamate tail. 
Embryonic, fetal and infant growth occurs more rapidly than 
at any other stage of the life cycle. The anabolic activity that 
must occur during pregnancy and lactation to support this growth, 
and requisite DNA, RNA and amino acid biosynthesis dictates 
an elevated dietary requirement for folate. Folate, in the form 
of 5,10-methylene tetrahydrofolate, during DNA synthesis acts 
as a methyl donor for the enzyme thymidylate synthase which 
converts deoxyuridine monophosphate to thymidine mono-
phosphate (Fig. 2). Folate in the form of 10-formyl tetrahy-
drofolate is necessary for the synthesis of the purines adenine 
and guanine, the nucleic acid building blocks of DNA and RNA. 
The amino acids methionine, serine, glycine and histidine are 
likewise metabolized via folate-dependent reactions.
Folate in the form of 5-methyltetrahydrofolate, is involved in 
remethylation of homocysteine to methionine. The latter is a 
precursor for S-adenosylmethionine (SAM), the principle methyl 
group donor in the body. SAM is involved in methylating 
cytosine in DNA and is thought to play a key role in post- 
transcription regulation of gene expression. Myelin maintenance 
and neural function are likewise dependent on the methylation 
reactions involving SAM. 
Recommended Dietary Intake?
Folates are synthesized in plants and certain bacteria but not 
in mammalian cells, and thus, they must be obtained in the diet. 
The recommended dietary allowance (RDA=dietary intake 
sufficient to meet the requirements of 97-98% of healthy 
individuals) of folate for adults, is 400μg/day of dietary folate 
equivalents (DFEs) (Institute of Medicine, 1998). The concept 
of DFEs for folate was introduced in North America in 2000 
to account for the differences in bioavailability of synthetic folic 
acid and naturally occurring folates (Institute of Medicine, 1998). 
Compared to folic acid consumed alone (a relative availability 
of 100%), folic acid ingested with food or used as a fortificant 
is thought to be only ~85% available. In contrast, naturally 
occurring food folates are thought to be only ~50% available 
(Institute of Medicine, 1998; Pfeiffer et al., 1997). Thus, folic 
acid is calculated to be 1.7 (85 divided by 50) more available 
than naturally occurring food folates. Hence, in order to convert 
all forms of dietary folate into DFEs, the following calculation 
was developed: μg of DFEs provided = μg food folate + (μg folic 
acid × 1.7). The Estimated Average Requirement (EAR = dietary Gillian Lindzon et al. 165
Table 1. Estimated Average Requirements (EAR) and Recommended Dietary 







Adults (19-50 years) 320 400
Pregnant women (14-50 years) 520 600
Lactating women  450 500
1)  Dietary  Folate  Equivalents
intake that meets the biologic requirement for 50% of the 
population) and the RDA are comparable for men and women, 
yet they differ when compared to the recommendations for 
pregnant and lactating women (Institute of Medicine, 1998). The 
RDA for pregnant and lactating women is 600 and 500 μg/day 
DFE, respectively, compared to 400 μg/day for nonpregnant 
nonlactating women (Institute of Medicine, 1998; Table 1). 
Folate During The Periconceptional Period
Neural tube defects
A fetus’ spinal cord and brain develop from the neural tube, 
which forms between seventeen and thirty days after conception, 
often before most women realize they are pregnant (Institute of 
Medicine, 1998). Spina bifida and anencephaly, the two most 
common neural tube defects, occur when the neural tube does 
not close properly. Spina bifida is a congenital defect in the spinal 
column, characterized by the absence of the vertebral arches 
through which the spinal membranes and spinal cord may 
protrude. Anencephaly, on the other hand, is characterized by 
an absence of the brain and cranial vault, with the cerebral 
hemispheres completely missing or greatly reduced in size. 
A relationship between NTDs and sub-optimal folate status was 
first proposed over 30 years ago by Smithells et al. (1976). 
Following a series of aggressively challenged cohort, case 
control, non-randomized control studies and a small randomized 
control trial, two major randomized clinical control trials: one 
co-ordinated by the UK Medical Research Council and the other 
conducted in conjunction with the Hungarian Family Planning 
program produced a flurry of public policy activity in North 
America regarding the use of folic acid during the pericon-
ceptional period (Czeizel, 1993; MRC Vitamin Study Research 
Group, 1991; Picciano et al., 1994). The UK Medical Research 
Council Study (1991) was an international multicentre (33 
centres) randomized double blind prevention trial (n=1,817) 
which demonstrated that supplementation with 4 mg/day of folic 
acid during the periconceptional period resulted in a three-fold 
reduction in NTDs among women who had experienced a 
previous NTD-affected pregnancy (MRC Vitamin Study Rese-
arch Group, 1991). Specifically in this high risk population, the 
recurrence rate was only 5 in 593 women who received a folic 
acid supplement and 21 of 602 who did not. In the Hungarian 
study, women (n=4,156) without a previous NTD-affected 
pregnancy and planning to become pregnant again were randomly 
assigned to receive a multivitamin-mineral supplement (including 
0.8mg of folic acid) or a placebo (no folic acid but contained 
copper, manganese, zinc and vitamin C) (Czeizel, 1993). Parti-
cipants of this study were defined as fully compliant if they took 
the supplements for at least 28 days before conception and 
continued taking them until the date of the second missed 
menstrual period. Six cases of NTDs were found in the placebo 
group (n=2,104); whereas, no NTDs were reported among peri-
conceptional multivitamin-mineral supplement users (n=2,052). 
These results suggest that for every 342 women treated with a 
folate-containing multivitamin-mineral supplement, one NTD 
would be prevented among women without a previous history 
of a NTD affected pregnancy.
The mechanism(s) how supplemental folic acid reduces the risk 
of a NTD is unclear; however as described by Blom et al. (2006), 
it may involve folate’s role in methylation of DNA-“the 
methylation hypothesis”. Briefly this hypothesis suggests that the 
enzyme methylene tetrahydrofolate reductase (MTHFR) sits at 
an important juncture in folate metabolism and depending on 
its activity may preferentially shunt one-carbon units toward 
either (1) methylation (production of SAM) or (2) thymidine and 
purine synthesis (production of DNA and RNA) (Fig. 2). 
Identification of a common single nucleotide polymorphism 
(SNP) in the MTHFR gene (677C >T) and our understanding 
of how this polymorphism may shunt folate in the direction of 
DNA and RNA biosynthesis versus SAM is consistent with the 
“methylation” hypothesis. Likewise, observations of reduced 
global DNA methylation and an increased NTD risk among 
carriers of the MTHFR 677C >T polymorphism in some, but not 
all studies, adds further credibility to the “methylation” hypo-
thesis. In their meta-analysis of available studies, Blom et al 
report that women homozygous for the 677C >T MTHFR variant 
(677TT) have a 60% increased risk of an NTD-affected 
pregnancy. 
Other congenital anomalies
While few in number, studies are available in the literature 
that link maternal folate status with other aberrations in early 
embryonic development. Such investigations include examination 
of the role of folate in congenital heart defects, urinary tract 
anomalies, limb defects and in unexplained recurrent early 
pregnancy loss to name a few. It is beyond the scope of this 
review to discuss each in detail but it is fair to say that while 
data from these studies are very interesting for most associations, 
the body of evidence is insufficient to make solid conclusions 
about them at this time (Botto et al., 1996; Czeizel, 1993; Czeizel, 
1996; Li et al., 1995; Shaw et al., 1995; Wouters et al., 1993). 
The reader is directed to the comprehensive review recently 
published by Tamura & Picciano (2006) for a systematic 
discussion of this literature. Two congenital anomalies where 
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origin to sub-optimal maternal folate status are orofacial defects 
(e.g. cleft lip and cleft palate) and Downs Syndrome.
Due to the success in preventing NTDs with folic acid 
supplementation (Tamura & Picciano, 2006), and speculation that 
orofacial structure and neurocrest closure may be linked, 
researchers have examined whether maternal folate nutrition 
and/or folic acid supplementation during the periconceptional 
period may have an impact on orofacial clefts. The critical period 
for fetal lip and palate formation is between 6 and 12 week of 
gestation. Tolarova (1982) reported a reduced re-occurrence 
(randomized control trial), and Czeizel et al. (1999) a reduced 
occurrence (prospective cohort study) of orofacial clefts in infants 
born to women supplemented with pharmacologic levels of folic 
acid (6-10 mg/d) during the periconceptional period. Recently 
Wilcox  et al. (2007) reported on a national population based 
case-control from Norway (n=377 infants with cleft lip with or 
without cleft palate; 196 infants with cleft palate alone; 763 
normal controls) in which folic acid supplements (>400 ug/d) 
during early pregnancy reduced the risk of isolated cleft lip (with 
or without cleft palate) by about a third. There was no effect 
of folic acid supplementation on cleft palate alone. Badovinac 
et al. (2007) in a meta-analysis of all published studies in English 
reported a protective effect of any level of folic acid suppl-
ementation during pregnancy on oral clefts. In contrast, Ray et 
al. (2003) reported no change in the risk for orofacial clefts pre- 
and post-folic acid fortification of the food supply in Canada. 
There is epidemiological evidence that the offspring of mothers’ 
homozygous for the 677C >T MTHFR variant may be at incre-
ased risk of orofacial clefts, especially among women with low 
folate intake in some (Mills et al., 1999; van Rooij et al., 2003), 
but not all studies (Jugessur et al., 2003; Shaw et al., 1998) 
In addition to the etiologic role of folate in NTDs and orofacial 
clefts, investigation of the relationship between maternal folate 
nutrition and frequency of Down syndrome has been an active 
area of research. Down Syndrome, or trisomy 21, results from 
an extra copy of chromosome 21, 95% of which is of maternal 
origin (Eskes, 2006). An increased prevalence of the 677C >T 
SNPs in the MTHFR gene among mothers who gave birth to 
a child with Down syndrome has been observed in many but 
not all populations examined (Eskes, 2006). Similarly it has been 
observed that the frequency of a methionine synthase reductase 
gene varient (A66A>G) is higher among mothers of children with 
Down syndrome than without and that the MTHFR 677C >T and 
methionine synthase A66A>G variants in combination in women 
may be predictive of an infant with Down syndrome. As with 
MTHFR, methionine synthase is a key enzyme in folate 
metabolism (Fig. 2). 
Folate During Pregnancy (Post-Closure of The Neural 
Tube)
Prior to the commencement of population-based initiatives in 
Canada to reduce the risk of folate-dependent NTDs (before 
1990), the primary consideration of public policy makers in 
relation to folate was to prevent the precipitous decline in 
maternal folate status that typically occurred in the 2
nd and 3
rd 
trimesters of pregnancy. The fact that the ONLY vitamin and/or 
mineral supplement recommended for adults by Health Canada, 
at any physiological state, was one for folic acid during 
pregnancy, underscores the level of concern regarding this 
phenomenon. 
Indeed, folate requirements are higher during anabolic periods 
of the life cycle including pregnancy and lactation, and in utero. 
Chanarin, followed by a host of others in the 1970’s, confirmed 
that pregnancy increased the requirement for folate which was 
not generally being met by a con-commitant increase in dietary 
folate intake (Chanarin, 1969). Folate requirements increase 
during pregnancy with an expansion of blood volume (~49%) 
and increased cellular proliferation as a result of uterine 
enlargement, placental development and fetal growth (Blackburn 
& Loper, 1992; Picciano et al., 1994). Prior to 1992 in Canada, 
women at their first prenatal visit (10-12 weeks after conception), 
but not before, were advised to take a folate-containing multi- 
vitamin mineral prenatal supplement (0.8-1.0 mg/d) for the 
duration of pregnancy. This supplement served to curb the decline 
in maternal blood folate concentrations during pregnancy and 
addressed possible clinical sequelae such as maternal mega-
loblastic anemia, placental abruption, pre-eclampsia, spontaneous 
abortion, stillbirth, poor fetal growth and premature delivery. A 
brief discussion of the evidence in support of the protective role 
of adequate maternal folate nutrition to promote normal fetal 
growth and prevention of premature delivery is provided below. 
The reader is once again referred to the review article by Tamura 
and Piccano (2006) for a detailed discussion of the weight of 
the evidence in support other clinical sequelae of suboptimal 
maternal folate nutrition.
Folate supplementation of pregnant women in a number of 
developing countries, where maternal dietary intake of folate are 
low, has been shown to increase infant birth weight and length, 
possibly mediated by improved placental development (Baumslag 
et al., 1970; Iyengar & Rajalakshmi, 1975). Likewise an asso-
ciation between maternal folate status and birth weight has been 
observed in the very economically and socially disadvantaged 
community of Camden New Jersey in the United States. Scholl 
et al reported that among 832 low-income women from Camden, 
those with mean dietary folate intakes below 240 μg/d had an 
approximate two-fold greater risk of preterm delivery and low 
infant birth weight than women with higher folate intakes (Scholl 
et al., 1996). The relationship between maternal folate nutritional 
status and birth weight in developed countries is not as consistent 
as observed in developing countries, likely reflecting a generally 
better overall plane of maternal folate nutrition. Interestingly, 
Vollset et al (Vollset et al., 2000) reported that women (n=5,883) 
in the upper quartile of plasma homocysteine concentration had 
an increased risk for delivering an infant prematurely (38%) or Gillian Lindzon et al. 167
of low infant birth weight (101%) as recorded in the Medical 
Birth Registry of Norway compared to women in the lowest 
quartile of plasma homocysteine concentration (p<0.005). Given 
that birth weight is probably the most significant predictor of 
infant mortality and morbidity in the first year of life, these 
observations have important public health implications (Wilcox, 
2001). 
All of the aforementioned studies examining the relationship 
between maternal folate status and clinical sequelae were 
conducted prior to folic acid fortification of the food supply in 
North America or were carried out in countries where folic acid 
fortification has not been initiated. As will be discussed in greater 
detail later in this review, mandatory folic acid fortification in 
North America has virtually eliminated folate deficiency among 
healthy, non-reproducing adults. This raises the question of 
whether, or not, post-folic acid fortification one would expect 
a decline in maternal folate status during pregnancy in the 
absence of a folic acid-containing supplement.
Folate During Lactation-Impact On The Nursing 
Infant
Breastfeeding is the gold standard and strongly preferred 
method of feeding infants. The World Health Organization and 
Health Canada recommends human milk as the exclusive nutrient 
source for full-term infants for the first 6 month of life and 
indicates that breastfeeding be continued at least through the first 
12 months of life and thereafter as long as mother and baby 
mutually desire (Health Canada, 2004; WHO, 2001). The 
scientific rationale for recommending breastfeeding as the 
preferred feeding choice for infants stems from its acknowledged 
benefits to infant nutrition, gastrointestinal function, host defense, 
neurodevelopment and psychological, economic and environ-
mental well-being (American Academy of Pediatrics, 2005; 
Kleinman, 2004). In contrast to that of pregnancy, research 
regarding the folate requirements of women during lactation has 
received very little attention. What does appear clear from the 
literature, however, is that milk folate levels are maintained at 
the expense of maternal folate reserves, except in the most severe 
cases of maternal folate deficiency (e.g. megaloblastic anemia). 
Hence, under usual circumstances the nursing infant is protected 
from maternal folate inadequacy (O'Connor et al., 1997). Milk 
folate concentrations in the literature do vary considerably (50 
to 320 nmol/L) likely reflecting differences in sample storage 
and assay conditions, timing of milk sample collection and the 
variability among the different population samples studied 
(O'Connor  et al., 1991; O'Connor et al., 1997). Milk folate 
concentrations are known to increase with the duration of 
breastfeeding and from morning to night and they are lower in 
fore- versus hindmilk. 
Because of the preferential partitioning of folate for milk 
synthesis, if maternal dietary folate intake is limiting during 
lactation, the concern is with the nutritional status and health 
of the mother herself and the impact of this on subsequent 
pregnancies. In addition to the amount of folate transferred into 
milk, women need extra folate during lactation to facilitate the 
synthesis of other constituents in milk (e.g. protein synthesis). 
While dietary folate requirements on a daily basis are less than 
during pregnancy, they are significantly greater than that of 
non-pregnant/non-lactating women. Adherence to the WHO 
guidance on duration and exclusivity of breastfeeding, would 
result in a greater net requirement for folate during lactation 
versus pregnancy. Among women who do not consume a folic 
acid supplement during either pregnancy or lactation, one can 
expect a further decline in blood folate concentrations imme-
diately post-partum (Houghton et al., 2006; Mackey & Picciano, 
1999; Qvist et al., 1986). Mackey and Picciano (1999) assessed 
the effects of dietary and supplemental folate intakes during 
lactation and found that unsupplemented women at 6 months had 
lower values for red blood cell folate and hemoglobin concen-
trations than supplemented mothers and that plasma homo-
cysteine concentrations increased. Plasma homocysteine concen-
tration is a nonspecific functional indicator of folate status of 
which an increase is indicative of compromised folate status. 
Again most of what we know about maternal folate status during 
lactation comes from studies that were conducted pre-fortification 
of the food supply. How fortification of the food supply in 
Canada has affected folate status during lactation is described 
below.
Women at Increased Risk of Sub-Optimal Folate 
Nutrition
Where the food supply is not fortified with folic acid, several 
environmental factors have been associated with low blood folate 
concentrations. Nutritive factors include poor eating habits, low 
fruit and vegetable intake, stringent dieting for weight loss and 
food preparation practices which leech and breakdown endo-
genous folate content (eg. prolonged boiling or stewing of vege-
tables) (O'Connor, 1994; Picciano et al., 1994). Nonnutritive 
factors include drug and/or alcohol abuse, younger maternal age, 
past reproductive history (close birth spacing and number of 
pregnancies) and poverty. While a number of investigators report 
lower blood folate levels among smokers compared to non- 
smokers (Nakazawa et al., 1983; Ortega et al., 1994; Senti & 
Pilch, 1985; Witter et al., 1982); this relationship appears to be 
attenuated once researchers statistically control for dietary folate 
intake (Green et al., 1998b; Piyathilake et al., 1994). In other 
words, smokers may have poorer dietary folate intakes than 
non-smokers, and the reason they have lower blood folate 
concentrations may be due to their dietary folate intake and not 
smoking per se. Early studies also provided evidence that oral 
contraceptives may have negatively impact blood folate con-
centrations; however as the estrogen content of oral contra-168 Folate status of Canadian and Korean women
ceptives has declined, so has the strength of the relationship 
(Green  et al., 1998b; Sutterlin et al., 2003). 
In addition to nutritive and non-nutritive factors that can 
influence blood folate concentrations, several SNPs have been 
identified which may not only influence blood folate concen-
tration but the forms of folate available for metabolism. The most 
thoroughly studied of these SNPs, and the one with the greatest 
known impact on folate metabolism, is the 677C >T MTHFR 
variant discussed earlier in relation to Down Syndrome (Bailey, 
2003; Ueland et al., 2001). This polymorphism involves a 
cytosine (C) to thymidine (T) substitution at nucleotide position 
677, which is responsible for an alanine to valine substitution 
in the MTHFR enzyme (Frosst et al., 1995; Goyette et al., 1994). 
Intracellular folate homeostasis depends on MTHFR, a crucial 
enzyme in the folate pathway that catalyzes the irreversible 
conversion of 5,10-methyltetrahydrofolate to 5-methyltetrahy-
drofolate which results in the conversion of homocysteine to 
methionine (Jacques et al., 1996). Individuals with this mutation 
with marginal or poor intakes of dietary folate have higher plasma 
homocysteine and lower plasma folate concentrations than people 
with a wild type 677CC MTHFR gene (Blom, 1998). In North 
America, the MTHFR C677T polymorphism is a common 
mutation, with an allele frequency of approximately 35% (Friso 
et al., 2002; Frosst et al., 1995; Ma et al., 1997). Approximately 
12- 15% of Caucasian and Asians are homozygous (TT) for the 
mutation and up to 50% are heterozygous (CT) (Bailey, 2003; 
Ueland  et al., 2001). 
In many cases, the clinical sequelae described for the MTHFR 
C677T SNP are similar to that of folate deficiency. For instance, 
the presence of this SNP appears to be associated, at least in 
some studies, with an increased risk of cardiovascular disease, 
NTDs, adverse pregnancy outcomes, and Down Syndrome 
(Ueland et al., 2001). Further, the presence of the MTHFR C677T 
SNP appears to be related to the risk of cancers of the breast, 
endometrium, cervix, esophagus, stomach, and bladder (Kim, 
2000; Ueland et al., 2001). Typically individuals that are 
homozygous for the MTHFR C677T variant, exhibit reduced 
folate status as measured by red blood cell folate concentration 
(Parle-McDermott et al., 2006). Regardless of folate status, the 
forms of folate in red blood cells do seem to be affected by 
this SNP (ie increase non-methylated forms with the variant), 
and it is speculated this may result in the redirection or 
preferential partitioning of folate through folate-dependant 
biochemical pathways (Davis et al., 2005; Smith et al., 2006; 
Smulders  et al., 2007). 
Choi  et al. (2006) investigated the relationship between the 
MTHFR C677T SNP and the folate status of Korean women 
of childbearing age. These investigators found that neither the 
C677T nor an A1298C SNP in the MTHFR gene were strongly 
associated with decreased plasma folate concentration or elevated 
plasma homocysteine concentration. However, the A1298C 
polymorphism did significantly influence red blood cell folate 
concentration, more so than the C677T polymorphism. A study 
done by Kim et al. (2004) investigated the effect of the 
interaction between the MTHFR C677T SNP and serum B 
vitamin levels on serum homocysteine levels in pregnant Korean 
women (n=177). They reported that serum homocysteine levels 
in these women varied significantly with MTHFR genotype and 
serum folate levels. As others have concluded, these researchers 
suggest that better maternal folate and B12 status may lessen 
the effect that the MTHFR genotype has on serum homocysteine 
levels.
What is the History of Folic Acid Fortification in 
Canada? 
Periconceptional folic acid supplementation reduces the risk 
of NTDs by 50%-70% (Czeizel, 1993; Lumley et al., 2001; MRC 
Vitamin Study Research Group, 1991), yet many women do not 
take folic acid supplements before conception (Honein et al., 
2001; Mathews et al., 1998). Despite many public-health 
campaigns in North America, a significant portion of women of 
reproductive age remain unaware of the importance of folic acid 
supplementation in prevention of NTDs and an even higher 
proportion, 65-65% do not follow recommendations despite this 
knowledge (Bailey et al., 2003; Lindsey et al., 2005). In fact, 
the March of Dimes in a Gallup Survey of American women 
(n=2,617), reported a reduction in daily folic acid supplement 
use between 2004 (40%) and 2005 (35%) (Lindsey et al., 2005). 
The proportion of American women of childbearing age that had 
knowledge the relationship between folic acid and birth defects 
remained unchanged at 25%. In a study conducted in the Ca-
nadian province of Quebec, 70% of pregnant women (n=1,240) 
reported they were aware of the role of folic acid in prevention 
of NTDs but only 25% had taken the recommended dose of folate 
during the periconceptional period (Morin et al., 2002). Groups 
of Canadians, particularly noncompliant with periconceptional 
folic acid supplement, are these of low educational status, youn-
ger women, immigrants and women with unplanned pregnancies.
Since folic acid awareness does not necessarily translate into 
behaviour change, and since neural tube closure occurs by the 
fourth week of pregnancy, a time when many women are unaware 
that they are pregnant, public health policy makers in Canada, 
in November 1998, mandated the fortification of white flour, 
enriched pasta and cornmeal with folic acid (Regulatory impact 
analysis statement, 1998). This intervention was expected to 
increase the average daily folic acid intake of women of 
childbearing age by 100 μg with almost nobody receiving more 
than 1 mg. 
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Fig. 3. Quarterly prevalence of open neural tube defects(upper), spina 
bifida(middle), and anencephaly (lower) before and after (vertical dashed lines) 
folic acid food fortification. [reprinted  with  permission  (Ray  et  al.,  2002a)]
Fig. 4. Rates of neural tube defects before and after fortification in regions 
with mandatory folic acid fortification.  Numbers  include  livebirths,  stillbirths, 
prenatally diagnosed cases and elective abortions (Chile with livebirths and stillbirths 
only  ,USA  with  surveillance  programmes  with  and  without  prenatal  assessment) 
(reprinted  with  permission).  [diagram  modified  with  permission  (Eichholzer  et  al., 
2006)]
Folate status
Ray  et al. (2002a, 2002b) has extensively studied the effect 
of the Canadian folic acid fortification program on the folate 
status of adults. In a retrospective review of red blood cell 
concentrations (n=8,884) from a large laboratory database (MDS 
Laboratories), Ray et al. (2002b) reported that the mean red blood 
cell folate concentration rose from 680 (CI 669-692) nmol/L 
pre-fortification to 852 (841-862) nmol/L post-fortification of the 
food supply. The MDS laboratories, located in Toronto, Canada, 
provide diagnostic services to approximately one-third of 
community-based patients in the province of Ontario. The mean 
age of patients in this sample was 57.4 years and approximately 
55% were women. The clinical reasons why the red blood folate 
concentrations were requested was not specified in the paper. 
In a second paper, Ray et al. (2002c) reported that the red blood 
cell folate concentrations of women (mean age 31.8 years [18-42 
years]) from the same laboratory database pre- and post- 
fortification increased from 527 nmol/L to 741 nmol/L. Folate 
concentrations in both these reports were measured by a 
competitive protein binding assay with a maximum reporting 
limit of 1,450 nmol/L. In a population-based study from the 
province of Newfoundland in Canada, Liu et al. (2004) reported 
that the red blood cell folate concentrations of reproductive-aged 
women increased from 625 (CI 601-649) nmol/L pre-fortification 
to 818 (784-854) nmol/L post-fortification of the food supply. 
Folic acid fortification of foods has taken place in the US, Costa 
Rica and Chile and similar, or higher, increases in blood folate 
concentrations have been reported (Chen & Rivea, 2004; Chou-
menkovitch et al., 2001; Choumenkovitch et al., 2002; Hertrampf 
& Cortes, 2004; Hirsch et al., 2002; Jacques et al., 1999; Ray, 
2004).
Canadian studies report a significant reduction in NTDs since 
folic acid fortification of the food supply. In the province of 
Quebec, De Wals et al. (2003) noted a 32% reduction in affected 
live births, elective terminations, and stillbirth certificates. Not 
all NTD cases may have been identified in this study due to 
the nonspecific manner in which deaths were classified. In the 
province of Ontario, Ray et al. (2002a) reported a 48% reduction 
in NTDs using antenatal screening records and a hospital 
discharge database to identify cases (Fig. 3). Gucciardi et al. 
(2002) examined the reduction of NTDs post folic acid 
fortification by enumerating cases reported in live birth, stillbirth, 
and hospital (but not clinic) therapeutic abortion records from 
the province of Ontario. This group found a 47% reduction in 
NTDs from 1995 to 1999. Lastly, Persad et al. (2002) investi-
gated records of all livebirths, stillbirths and terminated pregn-
ancies in the province of Nova Scotia from 1991 to 2000 and 
found a 54% decrease. Based on these studies, the fortification 
program appears to be preventing approximately 50% of NTDs 
which was the target goal for the policy. A study done by House 
et al. (2006) in the province of Newfoundland, where the 
incidence of NTDs have been historically high, showed a 
significant reduction in the number of NTDs from 4.67 
(1992-1996) to 1.01 (1998-2002) per 1,000 total births.
Necessity of Using Folic Acid-Containing Supplements 
Post Folic Acid Fortification of the Food Supply in 
Canada 
As described above, prior to folic acid fortification of foods 
in North America, most pregnant and lactating women in Canada 
did not meet the recommended levels of folate intake from dietary 
sources alone. As such, health experts recommended that women 
take a folic acid-containing supplement while planning a preg-
nancy, and for the duration of pregnancy. No recommendations 
existed specific for lactation but many physicians further 
recommended that supplementation should be continued during 170 Folate status of Canadian and Korean women
Table 2. Major contributors of folate (μg, uncorrected for bioavailability) in the 
diets of a sample of Canadian pregnant (n=61) and lactating women (n=60) 
(Sherwood  et al., 2006)




1 Orange juice 11.1 11.1
2 Pasta 8.8 19.9
3 Green salad 5.2 25.1
4 Bagels, english muffin 5.0 30.1
5 Whole wheat, rye and other dark bread 4.8 34.9
6 Cold cereal 4.5 39.4
7 White breads 4.2 43.6
8 Cream, milk and eggnog 3.9 47.5
9 Rice 3.8 51.3
10 Cakes, cookies, doughnuts and pies 3.3 54.6
Table 3. Major contributors of folate (μg, uncorrected for bioavailability) in the
diets of healthy Korean college females age 18-27 years (n=62) (Han et al.,
2005)
Rank Source  % of total folate Cumulative % of folate
1K i m c h i 2 1 2 1
2 Cooked rice 9 30
3 Egg, boiled 9 39
4 Strawberry, raw 8 47
5 Laver, toasted 4 51
6 Cow’s milk 3 54
7 Spinach, boiled 2 56
8 Soy bean sprout, boiled 2 58
9 Ramen (instant noodle) 2 60
10 Red bean paste 1 61
lactation. Currently in Canada women are advised to consume 
a multi-vitamin containing 400 μg folic acid during the peri-
conceptional period, for the duration of pregnancy and lactation 
(Health Canada, 2007). As available data suggest that many 
reproductive-age women continue to have red blood cell folate 
concentrations below 906 nmol/L, a value early in pregnancy 
shown to be an indicator of reduced risk of a NTD-affected 
pregnancy, advice by Health Canada for women to continue 
taking a folic acid-containing supplement during the pericon-
ceptional period seems prudent. Whether women continue to need 
a folic acid-containing supplement after closure of the neural 
tube, and during lactation since folic acid fortification of the food 
supply is less certain. Data from our own research group suggests 
that at mandated levels of folic acid fortification about one-third 
of well educated women still do not consume enough folate 
during pregnancy (post closure of the neural tube) and lactation 
from dietary sources alone (Sherwood et al., 2006). As actual 
levels of folic acid fortification of food in Canada may greatly 
exceed mandated levels (Quinlivan & Gregory, 2003b); the actual 
prevalence of inadequate intakes may be much lower. As 
surprising as it may seem, no one has directly measured the 
amount of folate added to the food supply in Canada. If we 
assume the amount of folic acid fortification is double mandated 
levels, as has been predicted by some in the United States, no 
women in our study would have had inadequate dietary intakes 
of folate (Sherwood et al., 2006). If this is, in fact true, a folic 
acid supplement is probably no longer necessary post-closure of 
the neural tube or during lactation unless a woman is capable 
of becoming pregnant. Therefore, one of the lessons learned from 
the Canadian folic acid experience is that it is crucial to determine 
and monitor the levels of folic acid that are used to enrich and 
fortify foods (Quinlivan & Gregory, 2003a). 
Dietary Sources Consumed by Women in Canada and 
Korea
Folates are present naturally in a variety of foods and occur 
in especially high levels in liver, dried peas and beans and green 
leafy vegetables including broccoli. Because of the volume 
consumed by North Americans, orange juice is often cited as 
the top contributor of naturally occurring folate in the diet 
(Sherwood  et al., 2006). Sherwood reported post-folic acid 
fortification that the breads and grains food group surpassed the 
fruits and vegetable group in terms of the contribution of folate 
in the diet of pregnant and lactating women (Table 2). Breads 
and grains contributed 41.0% of total dietary folate to the diets 
of pregnant and lactating women in the Sherwood et al. (2006) 
study whereas fruits and vegetables (non-beverage sources) 
provided 21.2% of total dietary folate intake. Dietrich et al. 
(2005) also recently reported that after fortification, the category 
“bread, rolls, and crackers” became the single largest contributor 
of total folate in the U.S. diet, contributing 15.6% of total intake, 
surpassing vegetables, which were the number one folate food 
source prior to fortification. 
Dietary habits differ considerably from country to country and, 
as such, the main sources of folate in a Korean diet differ greatly 
from those in a typical Canadian diet. As illustrated in Table 
3 in which the dietary intakes of college students from a study 
by Han et al. (2005) are summarized, kimchi is the top 
contributor of dietary folate (21% for females). Kimchi is a 
traditional fermented cabbage dish that is consumed at nearly 
every meal. In addition to the quantity of kimchi consumed, it 
is noteworthy it is also very high in folate (115 ug/100 g) (Yon 
& Hyun, 2003). Rice was the next largest contributor of folate 
to the diet of Korean female college students (9%). Han et al. 
(2005) report that vegetables are usually prepared by boiling in 
Korea, and they predict that cooking may destroy approximately 
29% of total dietary folate. It is difficult to predict the total 
intakes of dietary folate in Korea due to well described limitations 
in the food composition tables; however taking into account 
cooking losses, Han et al. (2005) estimated that the average folate 
intake of female college students was around 246 ug/d . This 
value is well below either the RDA (400 ug/d) or EAR (320 
ug/d) for folate and is strikingly similar to the reported folate 
intakes of Canadian reproductive age females pre-fortification of 
the food supply (Green et al., 1998a; O'Connor, 1994; Picciano Gillian Lindzon et al. 171
et al., 1994). Lim et al. (2000) measured the folate content in 
24 hour food composites collected by reproductive age Korean 
women (n=91) and reported folate intakes of 145.8 ug/d. 
Blood Folate Concentrations of Korean Women: are 
They Consistent with Prevention of Neural Tube 
Defects
In Korea, women consume a folic acid-containing supplement 
during pregnancy but as reported by Lee et al. (2005) most 
women (>80%) do not do so until after the 20
th week of 
pregnancy, long after the neural tube has closed (Lim et al., 
1999). Daly et al. (1995) report a maternal red blood cell folate 
above of 906 nmol/L during the periconceptional period is 
associated with a reduced risk of a NTD-affected pregnancy. 
Reported red blood cell folate concentrations of reproductive-age 
women in Korea fall well below this cut-off and are very similar 
to those reported for Canadian women pre-folic acid fortification 
of the food supply in Canada (Green et al., 1998a; Liu et al., 
2004; Ray et al., 2002). For example, Lim et al. (2000), Han 
et al. (2005) and Choi et al. (2006) report the mean red blood 
cell folate concentrations of Korean women of childbearing age 
to be 513+142, 772+240 and 450 nmol/L, respectively. In the 
first trimester of pregnancy, Lee reported the red blood cell folate 
concentration of women not consuming a folic acid-containing 
supplement to be 613+152 nmol/L. Chang et al. (1993) studied 
122 pregnant, lactating, and non-pregnant, non-lactating Korean 
women and found greater than 1/3rd had plasma folate 
concentrations falling below 6.8 nmol/L, a classic indicator of 
negative folate balance if maintained is a predictor of frank folate 
deficiency (eg. megaloblastic anemia). 
Rates of NTDs in Korea
Different methods of case ascertainment make comparison of 
the NTD rates between Korea and Canada impossible. There is 
some indication that the NTD rate in Korea may be lower than 
that in Canada pre-folic acid fortification of the food supply. 
Surveying representative members of the International Society 
for Pediatric Neurosurgery, Oi et al. (2003) reported a rate of 
spina bifida in Korea of 0.31 per 100,000 living Koreans 
compared to that of 1.27 per 100,000 Canadians. Using a Korean 
medical insurance database, Jung et al. (1999) reported the 
estimated prevalence of neural tube defects, including anen-
cephaly, spina bifida and encephalocele, was 0.67-0.77 per 1,000 
infants less than one year of age. In contrast, Ray et al. (2002) 
reported a reduction in the rate of open neural tube defects 
(anencephaly, spina bifida) from 1.13 to 0.58 per 1,000 preg-
nancies pre- to post-fortification in the province of Ontario, 
Canada. In the Canadian province with the highest rate of neural 
tube defects (Newfoundland), House et al. (2006) reported a 
reduction number of NTDs (anencephaly, spina bifida and 
encephalocele) from 4.67 to 1.01 per 1,000 total births. The latter 
two Canadian studies included pregnancies that were terminated 
early in their prediction of the NTD rate; our understanding of 
the Jung et al study is that they did not. Inclusion of terminated 
pregnancies in the NTD rates would increase the prevalence, but 
by how much is impossible to predict.
Recommendations and Conclusions
The purpose of this article was to describe the role of folate 
during female reproduction and specifically the periconceptional 
period, pregnancy (post-closure of the neural tube), and during 
lactation. The rationale for and history of recommending folic 
acid-containing supplements during the periconceptional period 
and pregnancy in Canada was described as was the folic acid 
fortification policy. Comparison of the published blood folate 
concentrations of reproductive-aged women in Korea suggests 
that their biochemical folate status is similar to those of Canadian 
women pre-fortification of the food supply. Certainly, the red 
blood cell folate concentrations of reproductive-age Korean 
women are well below that known to be maximally protective 
against neural tube defects. While a number of Korean authors 
acknowledge the significant limitations of currently available 
food composition tables to accurately estimate dietary folate 
intakes, estimated intakes appear to be inconsistent with those 
known to be protective against neural tube defects. The 
prevalence of neural tube defects may be lower in Korea than 
that in Canada pre-folic acid fortification of the food supply. 
Whether this reflects differences in genetic susceptibility for 
neural tube defects or merely differences in how cases of neural 
tube defects were attained remains to be determined. One of the 
significant lessons learned from the Canadian folic acid 
fortification experience over the last decade is the need to 
incorporate some form of on-going surveillance of actually how 
much folic acid is being added to the food supply. On-going 
surveillance is critical in evaluating the effectiveness and safety 
of the folic acid fortification strategy, and making adjustments 
to folate-containing supplements used in pregnancy and lactation.
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